{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:12:48Z","timestamp":1776103968392,"version":"3.50.1"},"reference-count":95,"publisher":"European Respiratory Society (ERS)","issue":"162","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ersjournals.com"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"published-print":{"date-parts":[[2021,12,31]]},"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is characterised by late-stage diagnosis and poor prognosis. Currently, no screening tool is advocated and diagnosis is based on invasive techniques, which are not well tolerated. Non-invasive diagnostic biomarkers have shown potential and could have a huge clinical benefit. However, despite extensive research, there is no consensus yet on their clinical use, with many articles reporting contradicting results, limiting their clinical implementation. The aim of this systematic review is therefore to explore the different semi- and non-invasive diagnostic markers in several human matrices and identify those that might clinically be relevant. A total of 100 articles were selected through Web of Science and PubMed, with 56 articles included in the quantitative analysis. Although many studies have reported on the diagnostic accuracy of MPM biomarkers such as serum mesothelin and high-mobility group box protein 1 and plasma fibulin-3, none have resulted in a validated test for early detection. Future research should focus on external validation, combinations into biomarker panels, the inclusion of early stage MPM patients and a combination of different biomarker matrices, as well as new markers.<\/jats:p>","DOI":"10.1183\/16000617.0057-2021","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T16:25:31Z","timestamp":1637166331000},"page":"210057","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis"],"prefix":"10.1183","volume":"30","author":[{"given":"Eline","family":"Schillebeeckx","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-8622","authenticated-orcid":false,"given":"Jan P.","family":"van Meerbeeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9500-7461","authenticated-orcid":false,"given":"Kevin","family":"Lamote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"2021111708250621000_30.162.210057.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00953-2019"},{"key":"2021111708250621000_30.162.210057.2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.086678"},{"key":"2021111708250621000_30.162.210057.3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0004563217741145","article-title":"Biomarkers in mesothelioma","volume":"55","author":"Arnold","year":"2018","journal-title":"Ann Clin Biochem"},{"key":"2021111708250621000_30.162.210057.4","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-0737"},{"key":"2021111708250621000_30.162.210057.5","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.lungcan.2005.03.020","article-title":"Soluble mesothelin-related protein - a blood test for mesothelioma","volume":"49","author":"Robinson","year":"2005","journal-title":"Lung Cancer"},{"key":"2021111708250621000_30.162.210057.6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"2021111708250621000_30.162.210057.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.01.002"},{"issue":"Suppl. 1","key":"2021111708250621000_30.162.210057.8","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.21037\/atm.2018.11.31","article-title":"Liquid biopsy in tumors: opportunities and challenges","volume":"6","author":"Bai","year":"2018","journal-title":"Ann Transl Med"},{"key":"2021111708250621000_30.162.210057.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2021111708250621000_30.162.210057.10","doi-asserted-by":"publisher","DOI":"10.1059\/0003-4819-155-8-201110180-00009"},{"key":"2021111708250621000_30.162.210057.11","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i02"},{"key":"2021111708250621000_30.162.210057.12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/172460081002500307","article-title":"Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma","volume":"25","author":"Cristaudo","year":"2010","journal-title":"Int J Biol Markers"},{"key":"2021111708250621000_30.162.210057.13","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31821e1c08"},{"key":"2021111708250621000_30.162.210057.14","doi-asserted-by":"crossref","first-page":"3510984","DOI":"10.1155\/2017\/3510984","article-title":"A novel panel of serum biomarkers for MPM diagnosis","volume":"2017","author":"Bonotti","year":"2017","journal-title":"Dis Markers"},{"key":"2021111708250621000_30.162.210057.15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5301\/JBM.2011.8332","article-title":"Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels","volume":"26","author":"Cristaudo","year":"2011","journal-title":"Int J Biol Markers"},{"key":"2021111708250621000_30.162.210057.16","first-page":"1725354","article-title":"Plasma fibulin-3 as a potential biomarker for patients with asbestos-related diseases in the Han population","volume":"8","author":"Jiang","year":"2017","journal-title":"Dis Markers"},{"key":"2021111708250621000_30.162.210057.17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/cncy.21646","article-title":"Young investigator challenge: MicroRNA-21\/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology","volume":"124","author":"Cappellesso","year":"2016","journal-title":"Cancer Cytopathol"},{"key":"2021111708250621000_30.162.210057.18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1371\/journal.pone.0018232","article-title":"Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma","volume":"6","author":"Santarelli","year":"2011","journal-title":"PLOS One"},{"key":"2021111708250621000_30.162.210057.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2012.02.009"},{"key":"2021111708250621000_30.162.210057.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200511-1789OC"},{"key":"2021111708250621000_30.162.210057.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2144"},{"key":"2021111708250621000_30.162.210057.22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/172460080902400208","article-title":"Osteopontin is not a specific marker in malignant pleural mesothelioma","volume":"24","author":"Paleari","year":"2009","journal-title":"Int J Biol Markers"},{"key":"2021111708250621000_30.162.210057.23","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-07-0607"},{"key":"2021111708250621000_30.162.210057.24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/bmm-2017-0224","article-title":"Clinical evaluation of circulating miR-548a-3p and-20a expression in malignant pleural mesothelioma patients","volume":"12","author":"Matboli","year":"2018","journal-title":"Biomark Med"},{"key":"2021111708250621000_30.162.210057.25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e31828f696b","article-title":"Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer","volume":"8","author":"Muley","year":"2013","journal-title":"J Thorac Oncol"},{"key":"2021111708250621000_30.162.210057.26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5606\/tgkdc.dergisi.2019.17557","article-title":"Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos","volume":"27","author":"Dongel","year":"2019","journal-title":"Turk Gogus Kalp Damar Cerrahisi Derg"},{"key":"2021111708250621000_30.162.210057.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(00)00153-7"},{"key":"2021111708250621000_30.162.210057.28","first-page":"2139","article-title":"Droplet digital PCR as a novel system for the detection of microRNA-34b\/c methylation in circulating DNA in malignant pleural mesothelioma","volume":"54","author":"Sato","year":"2019","journal-title":"Int J Oncol"},{"key":"2021111708250621000_30.162.210057.29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-016-9868-1","article-title":"Evaluation of new biomarkers in the prediction of malignant mesothelioma in subjects with environmental asbestos exposure","volume":"194","author":"Demir","year":"2016","journal-title":"Lung"},{"key":"2021111708250621000_30.162.210057.30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1515\/labmed-2015-0032","article-title":"Improved diagnosis of mesothelioma by a combination of soluble mesothelin-related peptide and CYFRA 21-1","volume":"39","author":"Holdenrieder","year":"2015","journal-title":"Laboratoriums Medizin"},{"key":"2021111708250621000_30.162.210057.31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00408-013-9526-9","article-title":"Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos","volume":"192","author":"Bayram","year":"2014","journal-title":"Lung"},{"key":"2021111708250621000_30.162.210057.32","first-page":"4343","article-title":"Cytokeratin 19 fragment\/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma","volume":"30","author":"Suzuki","year":"2010","journal-title":"Anticancer Res"},{"key":"2021111708250621000_30.162.210057.33","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M113.030775"},{"key":"2021111708250621000_30.162.210057.34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5152\/ejp.2017.50023","article-title":"Predicting malignant mesothelioma by analyzing serum N-ERC\/mesothelin, C-ERC\/mesothelin, hyaluronan, osteopontin, and syndecan-1 levels","volume":"19","author":"Arslan","year":"2017","journal-title":"Eurasian J Pulmonol"},{"key":"2021111708250621000_30.162.210057.35","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00148211"},{"key":"2021111708250621000_30.162.210057.36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7314\/APJCP.2014.15.1.363","article-title":"CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause","volume":"15","author":"Wang","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"2021111708250621000_30.162.210057.37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072030"},{"key":"2021111708250621000_30.162.210057.38","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fonc.2019.00740","article-title":"Liquid biopsy in malignant pleural mesothelioma: state of the art, pitfalls, and perspectives","volume":"9","author":"Cavallari","year":"2019","journal-title":"Front Oncol"},{"key":"2021111708250621000_30.162.210057.39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5301\/JBM.2011.8614","article-title":"Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide","volume":"26","author":"Dipalma","year":"2011","journal-title":"Int J Biol Markers"},{"key":"2021111708250621000_30.162.210057.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0629"},{"key":"2021111708250621000_30.162.210057.41","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318187491c"},{"key":"2021111708250621000_30.162.210057.42","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.079327"},{"key":"2021111708250621000_30.162.210057.43","first-page":"7425","article-title":"Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology","volume":"34","author":"Franceschini","year":"2014","journal-title":"Anticancer Res"},{"key":"2021111708250621000_30.162.210057.44","first-page":"2707","article-title":"Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma","volume":"33","author":"Ferro","year":"2013","journal-title":"Anticancer Res"},{"key":"2021111708250621000_30.162.210057.45","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-0422"},{"key":"2021111708250621000_30.162.210057.46","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.2010.066"},{"key":"2021111708250621000_30.162.210057.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2007.07.042"},{"key":"2021111708250621000_30.162.210057.48","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.lungcan.2015.09.021","article-title":"Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma","volume":"90","author":"Santarelli","year":"2015","journal-title":"Lung Cancer"},{"key":"2021111708250621000_30.162.210057.49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1130"},{"key":"2021111708250621000_30.162.210057.50","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318180477b"},{"key":"2021111708250621000_30.162.210057.51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12885-017-3209-5","article-title":"Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin","volume":"17","author":"Ak","year":"2017","journal-title":"BMC Cancer"},{"key":"2021111708250621000_30.162.210057.52","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181e392d7"},{"key":"2021111708250621000_30.162.210057.53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12885-017-3375-5","article-title":"Calretinin as a blood-based biomarker for mesothelioma","volume":"17","author":"Johnen","year":"2017","journal-title":"BMC Cancer"},{"key":"2021111708250621000_30.162.210057.54","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.068114"},{"key":"2021111708250621000_30.162.210057.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.02.007"},{"key":"2021111708250621000_30.162.210057.56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/874212","article-title":"Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum","volume":"35","author":"Creaney","year":"2013","journal-title":"Dis Markers"},{"key":"2021111708250621000_30.162.210057.57","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-428"},{"key":"2021111708250621000_30.162.210057.58","first-page":"5517","article-title":"YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis","volume":"33","author":"Corradi","year":"2013","journal-title":"Anticancer Res"},{"key":"2021111708250621000_30.162.210057.59","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200907-1020OC"},{"key":"2021111708250621000_30.162.210057.60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108054"},{"key":"2021111708250621000_30.162.210057.61","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0013"},{"key":"2021111708250621000_30.162.210057.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051185"},{"key":"2021111708250621000_30.162.210057.63","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jtcvs.2011.04.034","article-title":"Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma","volume":"142","author":"Watzka","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2021111708250621000_30.162.210057.64","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezs521"},{"key":"2021111708250621000_30.162.210057.65","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/ars.2011.3978","article-title":"Is Serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?","volume":"15","author":"Maeda","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"2021111708250621000_30.162.210057.66","first-page":"5756102","article-title":"Serum HMGB1 as a potential biomarker for patients with asbestos-related diseases","volume":"9","author":"Ying","year":"2017","journal-title":"Dis Markers"},{"key":"2021111708250621000_30.162.210057.67","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205205"},{"key":"2021111708250621000_30.162.210057.68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1115050"},{"key":"2021111708250621000_30.162.210057.69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19521-9"},{"key":"2021111708250621000_30.162.210057.70","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00408-019-00244-1","article-title":"Mesothelin, calretinin, and megakaryocyte potentiating factor as biomarkers of malignant pleural mesothelioma","volume":"197","author":"Jimenez-Ramirez","year":"2019","journal-title":"Lung"},{"key":"2021111708250621000_30.162.210057.71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1371\/journal.pone.0114483","article-title":"Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis","volume":"9","author":"Weber","year":"2014","journal-title":"PLOS One"},{"key":"2021111708250621000_30.162.210057.72","first-page":"9280170","article-title":"Circulating miR-132-3p as a candidate diagnostic biomarker for malignant mesothelioma","volume":"15","author":"Weber","year":"2017","journal-title":"Dis Markers"},{"key":"2021111708250621000_30.162.210057.73","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200811-1729OC"},{"key":"2021111708250621000_30.162.210057.74","doi-asserted-by":"crossref","first-page":"413946","DOI":"10.1155\/2014\/413946","article-title":"Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma","volume":"2014","author":"Creaney","year":"2014","journal-title":"Dis Markers"},{"key":"2021111708250621000_30.162.210057.75","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/07357907.2012.749265","article-title":"Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology","volume":"31","author":"Canessa","year":"2013","journal-title":"Cancer Invest"},{"key":"2021111708250621000_30.162.210057.76","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.medcli.2008.11.047","article-title":"Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions","volume":"133","author":"Aleman","year":"2009","journal-title":"Med Clin"},{"key":"2021111708250621000_30.162.210057.77","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3892\/etm_00000048","article-title":"Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma","volume":"1","author":"Fujimoto","year":"2010","journal-title":"Exp Ther Med"},{"key":"2021111708250621000_30.162.210057.78","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.21873\/anticanres.11460","article-title":"Comparison of the diagnostic performance of Fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma","volume":"37","author":"Battolla","year":"2017","journal-title":"Anticancer Res"},{"key":"2021111708250621000_30.162.210057.79","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31824c9272"},{"key":"2021111708250621000_30.162.210057.80","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12032-013-0543-6","article-title":"Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA","volume":"30","author":"Filiberti","year":"2013","journal-title":"Med Oncol"},{"key":"2021111708250621000_30.162.210057.81","doi-asserted-by":"crossref","first-page":"e0185850","DOI":"10.1371\/journal.pone.0185850","article-title":"Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: a retrospective study in a single center","volume":"12","author":"Otoshi","year":"2017","journal-title":"PLOS One"},{"key":"2021111708250621000_30.162.210057.82","doi-asserted-by":"publisher","DOI":"10.1177\/153303460900800502"},{"key":"2021111708250621000_30.162.210057.83","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(00)00157-0"},{"key":"2021111708250621000_30.162.210057.84","doi-asserted-by":"crossref","unstructured":"Bray BA . Chapter 11 - hyaluronan in the pulmonary alveolus and interstitium. In: Garg HG , Hales CA , eds. Chemistry and Biology of Hyaluronan. Oxford, Elsevier Science Ltd, 2004; pp. 247\u2013269.","DOI":"10.1016\/B978-008044382-9\/50042-X"},{"key":"2021111708250621000_30.162.210057.85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2019\/8628612","article-title":"MicroRNA signatures in malignant pleural mesothelioma effusions","volume":"2019","author":"Birnie","year":"2019","journal-title":"Dis Markers"},{"key":"2021111708250621000_30.162.210057.86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLOS One"},{"key":"2021111708250621000_30.162.210057.87"},{"key":"2021111708250621000_30.162.210057.88","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0129"},{"key":"2021111708250621000_30.162.210057.89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6671"},{"key":"2021111708250621000_30.162.210057.90","doi-asserted-by":"crossref","first-page":"520","DOI":"10.21037\/tlcr.2018.04.09","article-title":"Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review","volume":"7","author":"Brusselmans","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"2021111708250621000_30.162.210057.91","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.aca.2018.01.069","article-title":"Evolution of clinical and environmental health applications of exhaled breath research: Review of methods and instrumentation for gas-phase, condensate, and aerosols","volume":"1024","author":"Wallace","year":"2018","journal-title":"Anal Chim Acta"},{"key":"2021111708250621000_30.162.210057.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.04.009"},{"key":"2021111708250621000_30.162.210057.93","doi-asserted-by":"crossref","first-page":"435160","DOI":"10.1155\/2015\/435160","article-title":"Exhaled breath condensate: technical and diagnostic aspects","volume":"2015","author":"Konstantinidi","year":"2015","journal-title":"Scientific World J"},{"key":"2021111708250621000_30.162.210057.94","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00029705"},{"key":"2021111708250621000_30.162.210057.95","doi-asserted-by":"crossref","first-page":"030201","DOI":"10.1088\/1752-7163\/ab8a55","article-title":"The scientific rationale for the use of simple masks or improvised facial coverings to trap exhaled aerosols and possibly reduce the breathborne spread of COVID-19","volume":"14","author":"Pleil","year":"2020","journal-title":"J Breath Res"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0057-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:03:55Z","timestamp":1740373435000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0057-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":95,"journal-issue":{"issue":"162","published-online":{"date-parts":[[2021,11,17]]},"published-print":{"date-parts":[[2021,12,31]]}},"alternative-id":["10.1183\/16000617.0057-2021"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0057-2021","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]}}}